Clinical Trial Update: CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CBM588 in combination with nivolumab and cabozantinib for advanced or metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma

Drugs mentioned

• CBM588
• cabozantinib (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING